Lenalidomide added to bendamustine-rituximab for untreated chronic lymphocytic leukemia (CLL): A phase 1 study.

被引：0
|
作者：
Abramson, Jeremy S.
Davids, Matthew Steven
Werner, Lillian
Fisher, David Christopher
Armand, Philippe
Amrein, Philip C.
Neuberg, Donna S.
Hochberg, Ephraim P.
Brown, Jennifer R.
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7082
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Fludarabine, Rituximab, and Lenalidomide in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): A Phase I/II Trial of the Sarah Cannon Research Institute
    Flinn, Ian W.
    Cooper, R. Seth
    Thompson, Dana S.
    Waselenko, Jamie K.
    Reeves, James, Jr.
    Wise, Rudolph L.
    Hainsworth, John D.
    Berdeja, Jesus G.
    BLOOD, 2012, 120 (21)
  • [22] Bendamustine and Rituximab in combination with Lenalidomide in patients with relapsed or refractory and in patients with previously untreated chronic lymphocytic leukemia: A multicenter phase I/II safety and efficacy trial of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG)
    Pflug, N.
    Maurer, C.
    Bahlo, J.
    Kluth, S.
    Rhein, C.
    Cramer, P.
    Gross-Ophoff, C.
    Langerbeins, P.
    Fink, A. -M.
    Eichhorst, B.
    Kreuzer, K. -A.
    Tausch, E.
    Stilgenbauer, S.
    Boettcher, S.
    Doehner, H.
    Kneba, M.
    Hallek, M.
    Wendtner, C. -M.
    Bergmann, M.
    Fischer, K.
    Oncology Research and Treatment, 2015, 38 : 92 - 92
  • [23] Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
    Alexander Egle
    Michael Steurer
    Thomas Melchardt
    Lukas Weiss
    Franz Josef Gassner
    Nadja Zaborsky
    Roland Geisberger
    Kemal Catakovic
    Tanja Nicole Hartmann
    Lisa Pleyer
    Daniela Voskova
    Josef Thaler
    Alois Lang
    Michael Girschikofsky
    Andreas Petzer
    Richard Greil
    Annals of Hematology, 2018, 97 : 1745 - 1745
  • [24] BENDAMUSTINE PLUS RITUXIMAB IN 65 YEAR AND ABOVE UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
    De La Fuente, A.
    Beneit, P.
    Gutierrez, A.
    Callejas, M.
    Garcia Marco, J. A.
    Garcia Malo, M. D.
    de la Serna, J.
    Gonzalez Gascon y Marin, I.
    Garcia Sanchis, L.
    Ballesteros, M.
    Jarque, I.
    Ochoa Grullon, J.
    Iglesias, R.
    Estevez, M.
    de Ona, R.
    Prieto, E.
    Diaz-Lopez, A.
    Baltasar, P.
    HAEMATOLOGICA, 2016, 101 : 445 - 445
  • [25] Rate of major bleeding with ibrutinib versus bendamustine-rituximab in chronic lymphocytic leukemia: A population-based cohort study
    Dhopeshwarkar, Neil
    Yang, Wei
    Hennessy, Sean
    Rhodes, Joanna M.
    Cuker, Adam
    Leonard, Charles E.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (09) : E332 - E335
  • [26] Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/ Refractory or Previously Untreated Chronic Lymphocytic Leukemia
    Stilgenbauer, Stephan
    Morschhauser, Franck
    Wendtner, Clemens-Martin
    Cartron, Guillaume
    Hallek, Michael
    Eichhorst, Barbara F.
    Kozloff, Mark
    Giever, Thomas A.
    Lozanski, Gerard
    Punnoose, Elizabeth A.
    Wang, Jue
    Hilger, James
    Mobasher, Mehrdad
    Salles, Gilles
    BLOOD, 2016, 128 (22)
  • [27] Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG)
    Fischer, Kirsten
    Stilgenbauer, Stephan
    Schweighofer, Carmen D.
    Busch, Raymonde
    Renschler, Jasmin
    Kiehl, Michael
    Balleisen, Leopold
    Eckart, Michael J.
    Fink, Anna-Maria
    Kilp, Julia
    Ritgen, Matthias
    Boettcher, Sebastian
    Kneba, Michael
    Doehner, Hartmut
    Eichhorst, Barbara F.
    Hallek, Michael
    Wendtner, Clemens-Martin
    BLOOD, 2008, 112 (11) : 128 - 128
  • [28] Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): A multicentre phase II trail of the German CLL Study Group (GCLLSG).
    Fischer, Kirsien
    Stilgenbauer, Stephan
    Schweighofer, Carmen D.
    Renschler, Jasmin
    Busch, Raymonde
    Kiehl, Michael
    Balleisen, Leopold
    Eckart, Michael
    Fink, Anna M.
    Boettcher, Sebastian
    Ritgen, Matthias
    Kneba, Michael
    Staib, Peter
    Doehner, Hartmut
    Eichhorst, Barbara F.
    Hallek, Michael
    BLOOD, 2007, 110 (11) : 913A - 914A
  • [29] BENDAMUSTINE AND RITUXIMAB AS FIRST OR SECOND LINE THERAPY IN ELDERLY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Gozzetti, A.
    Ciolli, S.
    Candi, V.
    Breschi, C.
    Fabbri, A.
    Schiattone, L.
    Cencini, E.
    Papini, G.
    Raspadori, D.
    Defina, M.
    Aprile, L.
    Bosi, A.
    Bocchia, M.
    HAEMATOLOGICA, 2014, 99 : 592 - 592
  • [30] Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia
    Chavez, Julio C.
    Piris-Villaespesa, Miguel
    Dalia, Samir
    Powers, John
    Turba, Elyce
    Nodzon, Lisa
    Komrokji, Rami
    Sokol, Lubomir
    Locke, Frederick L.
    Lancet, Jeffrey
    Sotomayor, Eduardo M.
    Kharfan-Dabaja, Mohamed A.
    Pinilla-Ibarz, Javier
    LEUKEMIA RESEARCH, 2016, 47 : 78 - 83
12345